9SO.F

Healthcare Drug Manufacturers - Specialty & Generic

Solasia Pharma K.K.

€0.16

+0.01 +3.87% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 7, 2026, live at 10:25 AM ET	0.16

Key Stats

Market Cap

43.95M

Avg Volume

EPS

-€0.02

52W High

€0.22

52W Low

€0.09

Div. Yield

0.0%

Valuation

P/B Ratio

5.38

P/S Ratio

0.11

EV/EBITDA

1.37

EV/Revenue

-3.01

Margins

Gross Margin 50.3%

Operating Margin (13250.0%)

Net Margin (232.0%)

EBITDA Margin (220.4%)

Growth & Returns

Revenue Growth (YoY)

(91.7%)

Return on Equity

(66.0%)

Return on Assets

(29.6%)

Liquidity & Leverage

Current Ratio

4.28

Quick Ratio

3.47

Debt / Equity

0.05

Total Cash

1.29B

Total Debt

78.00M

About

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.